• Alondra Frías, Ignacio Gacitúa, Rubén Torres, Luis Toro, Erico Segovia, Miriam Alvo, Jorge Rodríguez, Carlos Romero, and María Eugenia Sanhueza.
• Sección de Nefrología, Hospital Clínico Universidad de Chile, Santiago, Chile.
• Rev Med Chil. 2022 Mar 1; 150 (3): 283-288.

BackgroundAnticoagulation in continuous renal replacement therapy (CRRT) is essential to counteract the coagulation cascade activation, induced by the dialysis circuit. Heparin is the most widely used anticoagulant, followed by regional citrate anticoagulation (RCA).AimTo determine the effectiveness and safety of anticoagulant treatment with citrate in CRRT.Material And MethodsRetrospective study of adults in CRRT hospitalized between the years 2014 and 2020 in critical units, who required change to RCA according to established protocols.ResultsWe studied 24 patients aged 63 ± 13 years (12 females). The reasons for admission were acute kidney injury (AKI) in 80% and stage 5 chronic kidney disease in 20%. The indication of RCA in 75% of patients was by coagulation of more than 3 circuits in 24 hours. The duration of the circuit in RCA was 18.5 ± 4.8 hours versus 11.9 ± 4.9 hours with heparin (p < 0.0001). There were 19 mild complications that did not affect the RCA.ConclusionsRCA is feasible to perform, it is a safe and efficient procedure if it is protocolized, allowing a longer duration of the dialysis circuit.

14 keywords...

hide…